RxDoctor Payments Data

Michelle Johnson

Family · Marquette, MINPI 1083015424

Payments from drug & device makers

$1,908in general payments, 2019–2025

Across 79 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$265
  • AstraZeneca$214
  • OPKO Pharmaceuticals, LLC$182
  • Insulet Corporation$144
  • Tandem Diabetes Care, Inc.$124
  • Bayer$114
  • plus $865 from 16 others

What the payments were for

  • Food & beverage$1,72690%
  • Education$18210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$21,783
Medicare patients
150
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$140,212
JardianceEmpagliflozin27$45,601
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$35,319
TymlosAbaloparatide11$29,346
MounjaroTirzepatide22$23,022
Tresiba Flextouch U-100Insulin Degludec21$21,255
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$18,790
Cinacalcet Hcl48$13,861
Humulin R U-500 KwikpenInsulin Regular, Human11$12,685
TrulicityDulaglutide11$12,052
FarxigaDapagliflozin Propanediol14$11,567
Novolog FlexpenInsulin Aspart23$11,184
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$10,576
NovologInsulin Aspart22$8,655
HumalogInsulin Lispro26$6,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$68$148,866143 claims
Boehringer IngelheimJardiance$75$45,60127 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$41$41,85159 claims
AstraZenecaFarxiga$214$11,56714 claims
AbbVieArmour Thyroid, Synthroid$19$4,60971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Marquette

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →